Dodge City

Researchers are evaluating the effectiveness of computerized cognitive training methods to help breast cancer survivors who experience cognitive difficulties related to cancer and its treatments. This trial focuses on breast cancer survivors with non-metastatic disease who report cognitive problems after their cancer therapy, aiming to address the long-lasting challenges that affect their work and health. The study is a Phase III, double-blind, randomized controlled trial comparing two types of cognitive training methods. Participants will be assigned to one of two groups. The first group will use global stimulation games featuring non-speeded, strategy-based exercises like solitaire, sudoku, and word search that do not adapt to the players skill. The second group will use neuroplasticity games designed to improve cognitive functions such as attention, working memory, processing speed, and executive function, with exercises that adapt to the users performance. The training involves eight exercises tailored to address cognitive concerns common among breast cancer survivors. During the study, participants will be monitored over 12 weeks post-randomization for self-reported cognitive impairment, with further assessments extending to 36 weeks. Researchers will collect data through cognitive tests, questionnaires, and behavioral tracking within the programs to measure changes in cognitive performance. The trial will also evaluate the safety and adherence to the training programs, with the total participation period lasting up to 36 weeks from randomization.

Researchers are collecting and storing tissue and blood samples from patients with various types of cancer to help create better models for studying cancer and testing new cancer drugs. This observational study focuses on patients with hematopoietic and lymphatic system neoplasms, malignant solid tumors, metastatic malignant solid tumors, and recurrent malignant solid tumors. The goal is to procure biological tissues and materials to develop preclinical cancer models for future laboratory analysis. During the study, tumor tissue and blood samples are collected during medical procedures required for the patients cancer treatment. These samples are then preserved using methods such as xenograft models, where tissues are transplanted to another species, or in vitro cell cultures. This process allows for future scientific study without additional invasive procedures beyond routine clinical care. Participants will be involved in routine clinical procedures during which tissue and blood samples are collected. Researchers will store these specimens and monitor their use in creating cancer models over a period of up to five years. The main outcome measured is the successful procurement and storage of tissue and blood specimens for research purposes. Participation will continue as long as samples can be collected during clinical management, with no additional treatment or interventions required specifically for this study.

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Researchers are evaluating whether observation alone is as effective as continuing treatment with pembrolizumab in preventing cancer recurrence in patients with early-stage triple-negative breast cancer TNBC who achieved a complete response after receiving chemotherapy combined with pembrolizumab before surgery. This phase III trial aims to compare these approaches in terms of recurrence-free survival, quality of life, and overall value of care. The study also examines side effects, survival rates, and financial impacts associated with the treatments. Participants are randomly assigned to one of two groups after completing neoadjuvant chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab treatment intravenously every 3 or 6 weeks for 27 weeks, while the other group undergoes observation without additional treatment during this period. Both groups will have tumor biopsies and blood samples collected, along with imaging tests like mammography, breast ultrasound, or MRI during follow-up. Throughout the study, participants will be monitored for cancer recurrence, survival, adverse events, and quality of life using questionnaires and assessments. Blood and tumor samples will help track biological markers. The primary outcome is recurrence-free survival over up to 10 years. Secondary outcomes include adverse event rates, overall survival, and local recurrence. Additional evaluations cover financial costs, work productivity, and patient-reported side effects. The total participation may involve long-term follow-up and several assessments over approximately 27 weeks and beyond.

Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.

Researchers are evaluating the optimal duration of HER2-targeted therapy for patients with early-stage HER2-positive breast cancer who have achieved a complete response after preoperative chemotherapy with trastuzumab. This phase III trial compares 6 months versus 12 months of combined neoadjuvant and adjuvant HER2 blockade to see if shorter therapy is as effective and to assess quality of life differences. The study also aims to evaluate side effects, recurrence rates, overall survival, and patient-reported outcomes related to symptoms and quality of life up to 10 years post-treatment. Participants are randomly assigned to one of two groups. One group receives trastuzumab and possibly pertuzumab intravenously or subcutaneously every 21 days for up to 17 cycles about 12 months, while the other group receives the same treatment for up to 9 cycles about 6 months. Treatments are given unless disease progresses or unacceptable toxicity occurs. Throughout the trial, participants undergo heart function tests echocardiography or MUGA, breast imaging mammography, ultrasound, or MRI, and may optionally provide blood and tissue samples. During the study, participants have regular assessments including quality of life questionnaires and monitoring for side effects. After treatment completion, follow-up visits occur every 6 months for 5 years or until cancer recurrence, then annually until 10 years from registration. Researchers measure recurrence-free survival, quality of life scores, adverse events, and survival outcomes. This long-term follow-up helps evaluate the lasting impact of shorter versus longer HER2-targeted therapy.

Researchers are evaluating the addition of pembrolizumab, an immunotherapy drug, to usual chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also assesses quality of life, side effects, and the impact of tumor markers on outcomes. Patients are randomly assigned to one of two active treatment groups. One group receives standard chemotherapy every 21 days for 4 cycles followed by pembrolizumab given intravenously every 21 days or every 6 weeks for up to 17 cycles. The other group receives chemotherapy combined with pembrolizumab during the initial 4 cycles, followed by pembrolizumab alone for additional cycles. Chemotherapy regimens include combinations of cisplatin, carboplatin, pemetrexed, gemcitabine, or paclitaxel. A previous group receiving chemotherapy alone followed by observation is closed. Participants undergo various assessments including echocardiograms, MRIs, CT scans, and blood sample collections during the trial. They complete quality of life questionnaires and are monitored regularly for disease recurrence, side effects, and survival for up to 10 years. Follow-up visits occur every 3 months for 2 years, then every 6 months for years 2 to 4, and annually thereafter, providing long-term monitoring of treatment effects and safety.

This trial investigates how well cabozantinib works when combined with two immunotherapy drugs, nivolumab and ipilimumab, in treating patients with rare genitourinary tumors that have spread from their original site. These cancers include various rare bladder, kidney, penile, and urethral cancers. The study aims to measure how effectively this combination can shrink tumors and improve survival, while also assessing safety and collecting tissue for further research. Participants receive cabozantinib pills daily on specific schedules during treatment cycles. Nivolumab and ipilimumab are given intravenously on set days during early cycles, with nivolumab continued alone afterward. Treatment cycles repeat every 21 days initially and then every 28 days for up to two years, unless the cancer worsens or side effects become unacceptable. Patients may undergo scans like CT, MRI, PETCT, and bone scans, as well as blood and urine tests throughout the study. During the study, patients have regular imaging and lab tests to evaluate tumor response and monitor health. Follow-up continues every two months for up to five years after treatment to assess outcomes such as tumor shrinkage, progression-free survival, overall survival, and side effects. The research team also supports tissue banking and evaluates treatment effects on bone disease. Safety and quality of life are monitored closely throughout this time.

Researchers are evaluating treatments for adults with newly diagnosed multiple myeloma, a type of plasma cell cancer. This phase III trial compares a four-drug combination including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug combination without bortezomib. The study aims to find out if adding bortezomib improves overall and progression-free survival, response rates, and patient quality of life while monitoring side effects and disease markers like minimal residual disease MRD. All participants first receive a standard induction therapy with daratumumab, lenalidomide, and dexamethasone over about 9 cycles of 28 days each. After this, patients are randomly assigned to one of two consolidation and maintenance treatments one group receives bortezomib along with the other drugs for consolidation followed by maintenance with daratumumab and lenalidomide the other group receives consolidation and maintenance without bortezomib. Treatments are given by subcutaneous injection or orally at specified days and cycles. Patients are followed long-term for up to 15 years after study entry. During the trial, patients undergo regular assessments including blood and urine tests, bone marrow biopsies, and imaging scans like PETCT to measure disease status and treatment response. Patient-reported outcomes on symptoms like neuropathy and quality of life are also collected. Safety is closely monitored through adverse event reports. Follow-up visits occur every 3 months initially, then less frequently over time to track survival and health outcomes.

Researchers are evaluating several drugs to treat patients with progressive meningiomas, a type of brain tumor that is growing, spreading, or worsening. This phase II trial focuses on how four different inhibitorsvismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclibwork in patients whose tumors have specific genetic mutations affecting cell growth pathways. The goal is to measure progression-free survival and response rates over six months to better understand their activity against these tumors. Participants are assigned to treatment groups based on their tumors mutation status. Patients with SMO or PTCH1 mutations receive vismodegib daily those with NF2 mutations get FAK inhibitor GSK2256098 twice daily patients with AKT1, PIK3CA, or PTEN mutations take capivasertib twice daily for four days each week in a 28-day cycle and those with CDK pathway alterations receive abemaciclib every 12 hours. Treatments continue in 28-day cycles until disease progression or unacceptable side effects occur. After treatment ends, participants are followed up every six months for up to five years. Throughout the study, participants undergo regular assessments, including imaging scans reviewed centrally to evaluate tumor response, as well as monitoring for adverse events. Researchers track overall survival, progression-free survival, and side effects to understand the drugs activity and safety. The study involves close monitoring of laboratory tests, heart function, and medication interactions to ensure participant safety during treatment and follow-up.